Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
sabato, ottobre 10
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Profound Medical Corp
PROF
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$6.90
-0.01
-0.14%
Ult. Agg.: Oct 9, 7:42 PM
$6.88
-0.0299
-0.43%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Profound Medical Financials
Profound Medical (PROF) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Profound Medical Sees Q3 Sales $9.800M-$10.000M vs $6.934M Est
Profound Medical (NASDAQ:PROF) sees Q3 sales of $9.800 million-$10.000 million vs $6.934 million analyst estimate.
Benzinga Newsdesk
PRO
Profound Medical Reports Q3 Preliminary Revenue Range $9.8M - $10M, Up ~85% To 89% YoY
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today
Benzinga Newsdesk
PRO
Profound Medical Affirms FY2026 Sales Guidance of $25.000M vs $26.858M Est
Profound Medical (NASDAQ:PROF) affirms FY2026 sales outlook from $25.000 million to $25.000 million vs $26.858 million estimate.
Benzinga Newsdesk
PRO
Profound Medical Q2 EPS $(0.26), Inline, Sales $2.483M Miss $5.500M Estimate
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.52) per share from the same period last year. The
Benzinga Newsdesk
PRO
Profound Medical Sees FY2026 Sales $25.000M
Profound Medical (CSE2: PRN) sees FY2026 sales of $25.000 million.
Benzinga Newsdesk
PRO
Profound Medical Q1 EPS $(0.19) Beats $(0.35) Estimate, Sales $5.337M Miss $6.648M Estimate
Profound Medical (TSX:PRN) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.35) by 45.71 percent. This is a 47.22 percent increase over losses of $(0.36) per share from the
Benzinga Newsdesk
